Recent advances in treating Parkinson’s disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722 · cited 1×
“That alpha-synuclein can spread in the human nervous sys-tem was reported in 2008 61 : Lewy bodies arise in healthy fetal mesencephalic cells several years after their transplantation into the striatum of patients with PD.”
BackgroundSeppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716 · cited 1×
“These developments include the improvement of the pump device for infusing L-Dopa in the jejunal cavity (likely available in 2017 or 2018 18 ) and the approval of a long-acting (5-to 6-hour duration of action) L-Dopa (currently available in the USA under the tradename Rytary 19–25 ; Table 1).”
BackgroundNeurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients
Iranzo, A., Fernández-Arcos, A., Tolosa, E., Serradell, M., Molinuevo, J. L., Valldeoriola, F., Gelpi, E., Vilaseca, I., Sánchez-Valle, R., Lladó, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089741 · Cited by 548 · cited 1×
“Whereas the first three are sensitive but not specific, RBD is now accepted as the most specific phenotype of the PD prodromal phases with a risk of more than 80% to convert into PD, or dementia with Lewy bodies (DLB) or less frequently into multiple system atrophy(MSA)—in 10 to 15 years 63,64 .”
BackgroundGenetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448 · cited 2×
“…for one of the autosomal-recessive genes for a mitochondrial dysfunction in PD ( PAKR2 , PINK1 , DJ1 ; for a comprehensive review on Mendelian and non-Mendelian inheritance of PD, see 59) or possess a mutation of the gene for glucocerebrosidase 1 ( GBA1 ) and thus are classified as PD-GBA1 65 .”
BackgroundNilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Hauser, R. A., Hsu, A., Kell, S., Espay, A. J., Sethi, K., Stacy, M., Ondo, W., O'Connell, M., & Gupta, S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70025-5 · Cited by 210 · cited 1×
“These developments include the improvement of the pump device for infusing L-Dopa in the jejunal cavity (likely available in 2017 or 2018 18 ) and the approval of a long-acting (5-to 6-hour duration of action) L-Dopa (currently available in the USA under the tradename Rytary 19–25 ; Table 1).”
BackgroundNicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Cited by
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 568
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 287
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Neuroprotective strategies for retinal disease
Pardue, M. T., & Allen, R. S. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.002 · Cited by 237
“While L-DOPA and dopamine agonists have long been used in the treatment of Parkinson's disease (Katzenschlager and Lees, 2002; Oertel, 2017), treatments to increase retinal dopamine levels as a neuroprotective strategy represent a novel and exciting avenue for retinal disease research.”
Metadata
- Authors
- Oertel, W. H.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2017-03-13
- Volume
- 6
- Pages
- 260
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W2594947121
- Cited by
- 123
- References
- 10
- FWCI
- 11.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in treating Parkinson’s disease. https://app.cochat.ai/papers/10.12688/f1000research.10100.1
- The paper
- Oertel, W. H. (2017). Recent advances in treating Parkinson’s disease. F1000Research. https://doi.org/10.12688/f1000research.10100.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.